RCS - Cambridge Cognition - CANTAB® success in Bristol Myers Squib research

Cambridge Cognition HoldingsAnnouncement

08/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250108:nRSH4615Sa&default-theme=true

RNS Number : 4615S  Cambridge Cognition Holdings PLC  08 January 2025

 

8 January 2025

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Cambridge Cognition highlights positive CANTAB(®) results in research by
Bristol Myers Squib

 

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group,
congratulates Bristol Myers Squibb, the global biopharmaceutical company, for
its recent FDA approval
(https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia)
(https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia)
of Cobenfy
(https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia)
(KarXT™ or Xanomeline and Trospium), and the exciting results published
recently in The American Journal of Psychiatry(1) showcasing the use of
Cambridge Cognition's CANTAB product in two Phase 3 clinical trials in
patients with schizophrenia.

 

Marking a significant advancement in schizophrenia treatment, Cobenfy is the
first new drug in decades and targets the M1 and M4 muscarinic receptors,
compared to antipsychotics which block dopamine receptors. This approach
reduces both the positive and negative symptoms of schizophrenia more
effectively(2).

 

CANTAB digital assessments provide accurate and objective measures of
cognitive function in clinical trials, enabling a more targeted approach. The
Company notes that Bristol Myers Squibb used data from CANTAB cognitive
assessments to conduct a post-hoc analysis of two-Phase 3 trials. This
analysis was recently published in The American Journal of Psychiatry(1)
titled 'The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment
in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials'.
 The CANTAB assessments showed improvement in patients with pre-specified
cognitive impairments after treatment with Cobenfy.

 

Cambridge Cognition believes this highlights CANTAB's effectiveness in
measuring cognitive performance improvements throughout the development of new
schizophrenia treatments. We remain committed to assisting pharmaceutical
companies in adopting CANTAB, enabling them to leverage cutting-edge study
designs and digital data capture technologies for more impactful research.

 

Rob Baker, Chief Operating Officer and Joint Managing Director at Cambridge
Cognition, commented:

"This is an important milestone in schizophrenia treatment's history, and we
are pleased to have been able to play a part. Importantly, this analysis
evidences how our digital assessment technologies can streamline data
collection, improve trial accuracy and ultimately accelerate the development
of effective treatments in schizophrenia."

 

 

References:

1.   Horan, William P., et al. "The Impact of Xanomeline and Trospium
Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled
Data From Two Phase 3 Trials." American Journal of Psychiatry (2024).

2.   Kaul, Inder, et al. "Efficacy and safety of the muscarinic receptor
agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA:
results from a randomised, double-blind, placebo-controlled, flexible-dose
phase 3 trial." The Lancet 403.10422 (2024): 160-170.

 

 

Enquiries:

 

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Chief Operating Officer and Joint Managing Director

 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Harry Griffiths                 cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Will Goode / Freddy Crossley / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / James Serjeant

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a leading technology company specializing in digital
health products that advance brain health research and treatment.

 

The company offers three core products: CANTAB® assessments-providing
scientifically validated, highly sensitive, precise, and objective measures of
cognitive function correlated to neural networks; a flexible and proven eCOA
platform with an extensive library of instruments, enabling efficient study
setup and scalable data capture; and quality assurance tools that ensure data
integrity by automatically detecting deviations in administration and scoring,
saving time and money. These products collectively improve clinical trial
outcomes, enable early patient identification, and enhance global efficiency
in healthcare and pharmaceuticals.

 

For further information, visit: www.cambridgecognition.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.cambridgecognition.com%2F&data=05%7C02%7Chgriffiths%40hudsonsandler.com%7Cc696c6a3150d40f91a9508dcfdd13b58%7Ca33bdb157e25438ab1fd5c523a8866f9%7C0%7C0%7C638664322305026349%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=vQVOIVxNQ8WYYOufDnSVKUH0oa7PLvXjnP0VT%2FzCfJc%3D&reserved=0)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLGDBBGGDGUR